Загрузка видео...

Не удалось загрузить видео

Возникла проблема при загрузке этого видео. Это может быть связано с временными проблемами сети или видео может быть недоступно.

На главную

Introducing #mBER: our open-source AI library for de novo, format-aware antibody design. Paired with in vivo multiplexed screening, mBER forms Manifold Bio's direct-to-vivo drug discovery platform, bridging the gap between AI-guided design and biological translation.

Manifold Bio

1,984 subscribers

15,504 просмотров • 9 месяцев назад •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

Комментарии: 0

Нет доступных комментариев

Здесь появятся комментарии из оригинального поста

Похожие видео

We recently released a technical report highlighting how Isomorphic Labs’ drug design engine is achieving a step change in how we model complex biological mechanisms, consistently outperforming industry benchmarks. Read our blog to discover how we’re bridging the gap between structure prediction and rational drug design. You can find the link in the comments.

We recently released a technical report highlighting how Isomorphic Labs’ drug design engine is achieving a step change in how we model complex biological mechanisms, consistently outperforming industry benchmarks. Read our blog to discover how we’re bridging the gap between structure prediction and rational drug design. You can find the link in the comments.

Isomorphic Labs

125,156 просмотров • 4 месяцев назад

One of the biggest unsolved problems in making medicines is what comes after AI design. Gleb Kuznetsov, cofounder and CEO of Manifold Bio, is tackling the in vivo bottleneck. Screening hundreds of thousands of antibody designs in a single animal changes what’s possible in drug discovery. I’ve known Gleb since he was my TA at MIT, so it was really fun to have him on Transcribed. We talked about: - Why he left Google to start over in biology (literally showing up at george church’s lab and asking how he could be useful) - How 3 companies came out of his grad school lab bay - What it takes to build a true platform company - Where AI-driven drug discovery is actually headed

One of the biggest unsolved problems in making medicines is what comes after AI design. Gleb Kuznetsov, cofounder and CEO of Manifold Bio, is tackling the in vivo bottleneck. Screening hundreds of thousands of antibody designs in a single animal changes what’s possible in drug discovery. I’ve known Gleb since he was my TA at MIT, so it was really fun to have him on Transcribed. We talked about: - Why he left Google to start over in biology (literally showing up at george church’s lab and asking how he could be useful) - How 3 companies came out of his grad school lab bay - What it takes to build a true platform company - Where AI-driven drug discovery is actually headed

Sajith Wickramasekara

10,659 просмотров • 5 месяцев назад

Must-know open-source and free tools for coders - Open source toggles library - Free motion design tool for web - Open-source API client - Open-source backend for AI apps - Git client for modern coding workflows

Must-know open-source and free tools for coders - Open source toggles library - Free motion design tool for web - Open-source API client - Open-source backend for AI apps - Git client for modern coding workflows

Csaba Kissi

16,314 просмотров • 9 дней назад

Open-source and free apps for coders - Open-source agentic development in one window - Free domain rating tracker - Open source framework for building AI agents - 158 design experiments - Free design inspiration

Open-source and free apps for coders - Open-source agentic development in one window - Free domain rating tracker - Open source framework for building AI agents - 158 design experiments - Free design inspiration

Csaba Kissi

49,249 просмотров • 3 дней назад

New Unsupervised Learning with Joshua Meier @ NeurIPS (Chai Discovery) on how AI x drug discovery is starting to inflect and: - The 3 waves of AI biotech - How AI models think differently than chemists - Building "Photoshop for molecules" - Deciding what to open source

New Unsupervised Learning with Joshua Meier @ NeurIPS (Chai Discovery) on how AI x drug discovery is starting to inflect and: - The 3 waves of AI biotech - How AI models think differently than chemists - Building "Photoshop for molecules" - Deciding what to open source

Jacob Effron

12,351 просмотров • 11 месяцев назад

Introducing Open Lovable v3 - an open source AI design engineer 🔥 Enter a URL and agents will create an on brand clone you can build on top of. Powered by Gemini 3 Pro and 's new branding format. Try out the 100% open source example, link below!

Developers Digest

178,165 просмотров • 7 месяцев назад

We raised $7.5M to kill AI slop. Introducing Moda: the world's first design agent with taste. RT+ comment “Moda” and we’ll design your brand for FREE.

Anvisha

4,518,466 просмотров • 3 месяцев назад

Where's Figma for graphic design? 🤔 Introducing Modyfi, a web-based collaborative image-making platform. Design, iterate, and review in a single place, combining layers, vectors, & bitmaps with AI and non-destructive real-time effects. 👉

Where's Figma for graphic design? 🤔 Introducing Modyfi, a web-based collaborative image-making platform. Design, iterate, and review in a single place, combining layers, vectors, & bitmaps with AI and non-destructive real-time effects. 👉

Alyssa X

232,305 просмотров • 2 лет назад

Molecular design for AI agents: announcing the Tamarind MCP Server. Today, scientists can use the Tamarind Bio library of 250+ molecular design tools(Boltz, AlphaFold, RFdiffusion...) in any AI chat interface. We serve not just open-source models, but the internal protocols your team has onboarded to Tamarind. Any tool added to Tamarind is then available across the MCP server, Tamarind web app, and API, so it can be used in chat-based agents, multi-step pipelines, ELNs, and LIMS-connected workflows. Our goal is simple: make Tamarind the place where scientists can access the BioAI tools they need, wherever they want to work, while we handle the infrastructure. Many users have already incorporated our MCP into their internal AI agents, along with community efforts like Blatant-Why building apps on top of Tamarind. Try out our tooling for antibody design, small molecule virtual screening, developability/ADMET scoring and more!

Molecular design for AI agents: announcing the Tamarind MCP Server. Today, scientists can use the Tamarind Bio library of 250+ molecular design tools(Boltz, AlphaFold, RFdiffusion...) in any AI chat interface. We serve not just open-source models, but the internal protocols your team has onboarded to Tamarind. Any tool added to Tamarind is then available across the MCP server, Tamarind web app, and API, so it can be used in chat-based agents, multi-step pipelines, ELNs, and LIMS-connected workflows. Our goal is simple: make Tamarind the place where scientists can access the BioAI tools they need, wherever they want to work, while we handle the infrastructure. Many users have already incorporated our MCP into their internal AI agents, along with community efforts like Blatant-Why building apps on top of Tamarind. Try out our tooling for antibody design, small molecule virtual screening, developability/ADMET scoring and more!

Deniz Kavi

14,502 просмотров • 3 месяцев назад

“Some of these research problems we’ve been going after really are holy grail predictive problems for drug design - and we’ve made some incredible breakthroughs there, which have really stunned our chemists.” On Sequoia Capital’s Training Data podcast, our Chief AI Officer Max Jaderberg talks about the scale of AI drug discovery and its potential to transform how we design new medicines. Listen to the full podcast at the link below:

“Some of these research problems we’ve been going after really are holy grail predictive problems for drug design - and we’ve made some incredible breakthroughs there, which have really stunned our chemists.” On Sequoia Capital’s Training Data podcast, our Chief AI Officer Max Jaderberg talks about the scale of AI drug discovery and its potential to transform how we design new medicines. Listen to the full podcast at the link below:

Isomorphic Labs

12,294 просмотров • 1 год назад

“In five years, doing drug design without AI will be like doing science without maths.” Max Jaderberg says the next frontier in drug discovery is collaboration with AI agents. You guide them. They search molecular space and return in hours with what would've taken humans weeks.

“In five years, doing drug design without AI will be like doing science without maths.” Max Jaderberg says the next frontier in drug discovery is collaboration with AI agents. You guide them. They search molecular space and return in hours with what would've taken humans weeks.

vitrupo

156,947 просмотров • 1 год назад

Fast, iterative product design isn't a pipe dream anymore. Bring your favorite AI agents directly into your canvas. Explore styles in seconds, edit hands-free with your voice, and bridge the gap between design and production instantly.

Fast, iterative product design isn't a pipe dream anymore. Bring your favorite AI agents directly into your canvas. Explore styles in seconds, edit hands-free with your voice, and bridge the gap between design and production instantly.

Mike Diarmid

1,434,508 просмотров • 3 месяцев назад

1) Introducing X1E 🧵 X1E is an AI-native investment agent built on an all-in-one platform to bridge the gap between equities and crypto.

1) Introducing X1E 🧵 X1E is an AI-native investment agent built on an all-in-one platform to bridge the gap between equities and crypto.

X1E

19,657 просмотров • 11 месяцев назад

Introducing Design OS—the missing design process between your idea and codebase. Step 1: Set your product vision Step 2: Design your screens Step 3: Export production-ready components Not mockups. Real components. Ready to build. Free & open source:

Introducing Design OS—the missing design process between your idea and codebase. Step 1: Set your product vision Step 2: Design your screens Step 3: Export production-ready components Not mockups. Real components. Ready to build. Free & open source:

Brian Casel

50,135 просмотров • 6 месяцев назад

🪄 Introducing Visual Copilot! A new era in bridging design to code.

🪄 Introducing Visual Copilot! A new era in bridging design to code.

Vishwas

85,670 просмотров • 2 лет назад

Introducing @designsdotAI An AI-powered platform that makes design accessible to everyone. Create a stunning marketing portfolio in under 2 minutes with intuitive tools. Check here:

Introducing @designsdotAI An AI-powered platform that makes design accessible to everyone. Create a stunning marketing portfolio in under 2 minutes with intuitive tools. Check here:

Nelly;

376,434 просмотров • 2 лет назад

Meet Simplified - Amplify Your Creative Power with Simplified AI Design Explore New Horizons with AI Design. Enhance your creative process and create AI Presentations, AI Carousels, Ad Banners with AI Design tools. Try for free:

Meet Simplified - Amplify Your Creative Power with Simplified AI Design Explore New Horizons with AI Design. Enhance your creative process and create AI Presentations, AI Carousels, Ad Banners with AI Design tools. Try for free:

Farhan

30,109 просмотров • 2 лет назад

Introducing "A Pattern Language for Agentic AI Skill Design."

Introducing "A Pattern Language for Agentic AI Skill Design."

Carlos E. Perez

81,695 просмотров • 3 месяцев назад

Introducing Silico: the platform for building AI models with the precision of written software. Silico lets researchers and engineers see inside their models, debug failures, and intentionally design them from the ground up. Early access is open now. 🧵(1/10)

Introducing Silico: the platform for building AI models with the precision of written software. Silico lets researchers and engineers see inside their models, debug failures, and intentionally design them from the ground up. Early access is open now. 🧵(1/10)

Goodfire

111,376 просмотров • 2 месяцев назад

The ambition at Isomorphic Labs is immense – they’re rethinking drug discovery from the ground up, using AI. 💊 Join Head of Medicinal Drug Design rebecca paul & Chief AI Officer Max Jaderberg as they share the possibilities of AI in tackling disease with host Hannah Fry. Watch their conversation ↓ Timecodes: 00:00 Intro 02:11 AI & Disease 05:30 AI in Biology 06:51 Molecules and Proteins 12:05 AlphaFold 3 14:40 Demo 16:20 Human-AI collaboration 24:30 Drug Design Challenges 39:00 Beyond Animal Models 44:35 AI Drug Future 46:30 Outro

The ambition at Isomorphic Labs is immense – they’re rethinking drug discovery from the ground up, using AI. 💊 Join Head of Medicinal Drug Design rebecca paul & Chief AI Officer Max Jaderberg as they share the possibilities of AI in tackling disease with host Hannah Fry. Watch their conversation ↓ Timecodes: 00:00 Intro 02:11 AI & Disease 05:30 AI in Biology 06:51 Molecules and Proteins 12:05 AlphaFold 3 14:40 Demo 16:20 Human-AI collaboration 24:30 Drug Design Challenges 39:00 Beyond Animal Models 44:35 AI Drug Future 46:30 Outro

Google DeepMind

78,008 просмотров • 1 год назад